Recurring and consumable sales - Co said Q2 recurring revenue rose 14% yr/yr and consumable revenue grew over 20%, supporting overall revenue growth
Margin initiatives - Co attributed record 15% Q2 gross margin to progress on margin expansion initiatives
System placements and validations - Four new Growth Direct systems placed and nine validations completed in Q2, with co citing strong customer engagement and enterprise deployment momentum
Quarterly results and guidance
U.S. life sciences automation provider's Q2 revenue grew 11% yr/yr, beating analyst expectations
Company reported record Q2 gross margin of 15%, up 11 percentage points yr/yr
Company reaffirmed full-year 2026 revenue and gross margin guidance
Key details and analyst coverage
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$8.1 mln
$7.88 mln (4 Analysts)
Q2 Loss Per Share
$0.27
Q2 Net Loss
Miss
$12.90 mln
$11.70 mln (2 Analysts)
Q2 Operating Expenses
$13.50 mln
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
RPID•
